Category Archives: Indian Patent Office

Drugs row threatens health sector budget

Source: Daily Nation; October 6, 2015 Kenya may be forced to increase its future annual health budget, if global drug companies have their way in the simmering patents row surrounding the manufacture of medicines. They have pushed India, Kenya’s biggest … Continue reading

Posted in EU-India FTA, Indian Patent Law, Indian Patent Office, IP Rights, IPR policy, LDCs, Uncategorized | Leave a comment

Maths of Gilead’s hepatitis C drug

Source: Down To Earth 3 Feb 2015 Why US firm’s super expensive drug sofosbuvir costs so much and how it can be made at a tenth of current price The indian Patent Office’s rejection of one of Gilead Sciences’ patents … Continue reading

Posted in Hepatitis C, Indian Patent Law, Indian Patent Office, Patent Opposition, Patents, Pricing, Sofosbuvir | Leave a comment

Gilead Sciences, Inc.’s (GILD) Sovaldi Faces Patent Opposition In India

Source: BidnessEtc 3 Feb 2015 Gilead is looking at another pre-grant opposition to its patent application for Sovaldi in India, on the grounds of the drug being ineffective Gilead Sciences, Inc.’s (NASDAQ:GILD) patent application for its hepatitis C drug, Sovaldi – … Continue reading

Posted in Hepatitis C, Indian Patent Law, Indian Patent Office, Patent Opposition, Patents | Leave a comment

India’s Patent Office Breaths New Life On The Production Of Hepatitis C Medication, Gilead Shot-Down In The Process

Source: The Science Times 22 Jan 2015 Hepatitis C is a blood-borne virus that’s often associated with pandemic like outbreaks in third-world countries, due to the viruse’s communicably when sterilization practices aren’t enforced. Once rampant inside the host’s body, the … Continue reading

Posted in Hepatitis C, Indian Patent Law, Indian Patent Office, Patents, Sofosbuvir | Leave a comment

TAC, SECTION27 AND MSF APPLAUD INDIA’S REJECTION OF PATENT ON NEW HEPATITIS C MEDICINE

Source: TAC 20 Jan 2015 – The rejection of a patent on sofosbuvir will allow India to produce more affordable generic versions – South Africa’s outdated laws prevent patent rejection, which could lead to artificially high prices until 2034 JOHANNESBURG, … Continue reading

Posted in Hepatitis C, Indian Patent Law, Indian Patent Office, Patents, Sofosbuvir | Leave a comment

Gilead to appeal Indian patent rejection on Hepatitis C drug

Source: Business Line 16 Jan 2015 California headquartered Glilead Sciences will appeal the Indian patent office decision to reject a patent application that covers Hepatitis C drug sofosbuvir. Earlier this week, the Indian patent office rejected a patent application on … Continue reading

Posted in Hepatitis C, Indian Patent Law, Indian Patent Office, Patents, Sofosbuvir | Leave a comment

Gilead’s reaction to recent Sofosbuvir Patent Rejection in India – The application was not that important!!!!

16 Jan 2015 Gregg Alton, executive Vice President, Corporate and Medical Affairs Gilead Sciences said: The main patent applications covering sofosbuvir are still pending before the Indian Patent Office. This rejection relates to the patent application covering the metabolites of … Continue reading

Posted in Hepatitis C, Indian Patent Office, IP Rights, Patents, Sec 3 (d) | Leave a comment